- Home
- HAFN vs MESO Comparison
HAFN vs MESO Comparison
Compare HAFN & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HAFN | MESO |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | Singapore | Australia |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HAFN | MESO |
|---|---|---|
| Price | $6.10 | $17.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $24.00 |
| AVG Volume (30 Days) | ★ 1.3M | 220.3K |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | ★ 6.50% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $2,221,808,000.00 | $17,198,000.00 |
| Revenue This Year | N/A | $576.59 |
| Revenue Next Year | $0.30 | $41.15 |
| P/E Ratio | $10.07 | ★ N/A |
| Revenue Growth | N/A | ★ 191.39 |
| 52 Week Low | $3.61 | $9.61 |
| 52 Week High | $6.64 | $21.50 |
Technical Indicators
Market Signals| Indicator | HAFN | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 62.87 | 43.12 |
| Support Level | $5.63 | $16.67 |
| Resistance Level | $6.25 | $19.34 |
| Average True Range (ATR) | 0.13 | 0.59 |
| MACD | 0.05 | -0.13 |
| Stochastic Oscillator | 76.42 | 20.22 |
Price Performance
Historical ComparisonAbout HAFN Hafnia Limited
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.